223555-87-1Relevant academic research and scientific papers
GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE
-
Paragraph 00488; 00489; 001353; 001354, (2021/01/22)
Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.
Oxidative C–H alkynylation of 3,6-dihydro-2H-pyrans
Zhao, Ran,Feng, Guidong,Xin, Xiaodong,Guan, Honghao,Hua, Jing,Wan, Renzhong,Li, Wei,Liu, Lei
, p. 1432 - 1434 (2019/03/28)
Current synthesis of α-substituted 3,6-dihydro-2H-pyrans dominantly relies on functional group transformation. Herein, a direct and practical oxidative C–H alkynylation and alkenylation of 3,6-dihydro-2H-pyran skeletons with a range of potassium trifluoro
ANTI-INFECTIVE COMPOUNDS
-
, (2015/02/25)
The present invention relates to small molecule compounds and their use in the treatment of bacterial infections, in particular Tuberculosis.
NOVEL INHIBITORS
-
, (2011/05/03)
The invention relates to novel pyrrolidine derivatives of formula (I): wherein R1, R2 and R3 are as defined herein, as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.
